Chemotherapy for Stage IV Sporadic Pancreatic Neuroendocrine Tumors (pNET): Are Partial Responses to Post-first Line Chemotherapy Predictable by Response/Type of First Line Chemotherapy?


Introduction: Three types of chemotherapy are recommended for stage IV pancreatic neuroendocrine tumors (pNETs): streptozocin (STZ)-, dacarbazine (DCZ)- and oxaliplatin (OX)-based. Whether cross resistance exists is unknown.

Aim(s): To analyze RECIST-response to second-line chemotherapy as a function of antitumor activity and type of first line chemotherapy.

Materials and methods: Multicenter retrospective study. Inclusion criteria were: 1)Confirmed pNET naive of therapy 2)RECIST measurable disease 3)Sporadic tumor. STZ- and DCZ- regimens were grouped together as alkylating agents.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Marotta V

Authors: Marotta V, Malka D, Walter T, Do Cao C, Faggiano A,

Keywords: pancreatic neuroendocrine tumor, chemotherapy,

To read the full abstract, please log into your ENETS Member account.